1191 related articles for article (PubMed ID: 33738989)
1. Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2.
Shu CJ; Huang X; Tang HH; Mo DD; Zhou JW; Deng C
Zool Res; 2021 Mar; 42(2):170-181. PubMed ID: 33738989
[TBL] [Abstract][Full Text] [Related]
2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
3. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
4. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
5. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
Huang SW; Miller SO; Yen CH; Wang SF
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
8. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
9. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
[TBL] [Abstract][Full Text] [Related]
10. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
11. Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex.
Ortuso F; Mercatelli D; Guzzi PH; Giorgi FM
J Biomol Struct Dyn; 2022 Sep; 40(14):6545-6555. PubMed ID: 33583326
[TBL] [Abstract][Full Text] [Related]
12. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity.
Lu J; Sun PD
J Biol Chem; 2020 Dec; 295(52):18579-18588. PubMed ID: 33122196
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
15. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
Borkotoky S; Dey D; Hazarika Z
Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
[TBL] [Abstract][Full Text] [Related]
16. Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.
Liu S; Chen H; Chen X; Luo N; Peraramelli S; Gong X; Zhang MJ; Ou L
Front Immunol; 2024; 15():1365803. PubMed ID: 38646520
[TBL] [Abstract][Full Text] [Related]
17. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
Lata S; Akif M
J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
Ge J; Zhang S; Zhang L; Wang X
Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45
Ratajczak MZ; Bujko K; Ciechanowicz A; Sielatycka K; Cymer M; Marlicz W; Kucia M
Stem Cell Rev Rep; 2021 Feb; 17(1):266-277. PubMed ID: 32691370
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.
Huang SW; Wang SF
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
